Where can I buy Innate Pharma shares?
Shares of IPHA can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab. Compare Top Brokerages Here. What is Innate Pharma's stock price today?
What is Innate Pharma’s pipeline?
Analyst Weighs In Innate Pharma SA is a biopharmaceutical company, which engages in improving oncology treatment and clinical outcomes for patients through therapeutic antibodies that harness the immune system to fight cancer. Its product pipeline include Lacutamab, Monalizumab, Avdoralimab, and IPH62.
What's new at Innate Pharma in 2022?
MARSEILLE, France, February 04, 2022--Innate Pharma to participate in upcoming investor conferences MARSEILLE, France, January 24, 2022--Number of shares and voting rights of Innate Pharma as of January 1, 2022 MARSEILLE, France, January 05, 2022--Innate Pharma obtains €28.7M in non-dilutive financing in the form of State Guaranteed Loans
How much non-dilutive financing did Innate Pharma obtain?
MARSEILLE, France, January 24, 2022--Number of shares and voting rights of Innate Pharma as of January 1, 2022 MARSEILLE, France, January 05, 2022--Innate Pharma obtains €28.7M in non-dilutive financing in the form of State Guaranteed Loans
Is IPHA stock a buy right now?
4 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for Innate Pharma in the last year. There are currently 4 buy ratings...
Will Innate Pharma's stock price go up in 2022?
4 Wall Street analysts have issued 12 month target prices for Innate Pharma's stock. Their forecasts range from $9.00 to $14.00. On average, they p...
How has Innate Pharma's stock performed in 2022?
Innate Pharma's stock was trading at $4.56 at the beginning of 2022. Since then, IPHA shares have decreased by 34.6% and is now trading at $2.98....
Who are Innate Pharma's key executives?
Innate Pharma's management team includes the following people: Dr. Mondher Mahjoubi M.D. , Chairman of Exec. Board & CEO (Age 64, Pay $1.1M) Mr....
What is Hervé Brailly's approval rating as Innate Pharma's CEO?
4 employees have rated Innate Pharma CEO Hervé Brailly on Glassdoor.com . Hervé Brailly has an approval rating of 100% among Innate Pharma's emplo...
Who are some of Innate Pharma's key competitors?
Some companies that are related to Innate Pharma include REGENXBIO (RGNX) , Sana Biotechnology (SANA) , Kymera Therapeutics (KYMR) , Editas Med...
What other stocks do shareholders of Innate Pharma own?
Based on aggregate information from My MarketBeat watchlists, some companies that other Innate Pharma investors own include Cidara Therapeutics (c...
When did Innate Pharma IPO?
(IPHA) raised $80 million in an IPO on Thursday, October 17th 2019. The company issued 10,700,000 shares at a price of $7.50 per share. Citigroup,...
What is Innate Pharma's stock symbol?
Innate Pharma trades on the NASDAQ under the ticker symbol "IPHA."
Number of Shares and Voting Rights of Innate Pharma as of February 1, 2022
Innate Pharma to Participate in Upcoming Investor Conferences
MARSEILLE, France, February 15, 2022--Number of shares and voting rights of Innate Pharma as of February 1, 2022
Number of Shares and Voting Rights of Innate Pharma as of January 1, 2022
MARSEILLE, France, February 04, 2022--Innate Pharma to participate in upcoming investor conferences
Innate Pharma Says Chemo-Free Monalizumab Triplet Therapy Shows Preliminary Anti-Cancer Activity
MARSEILLE, France, January 24, 2022--Number of shares and voting rights of Innate Pharma as of January 1, 2022
Innate Pharma: Monalizumab Combined With Cetuximab and Durvalumab Demonstrates Anti-Tumor Activity in First-Line Recurrent or Metastatic Head and Neck Cancer at ESMO Immuno-Oncology 2021 Congress
Innate Pharma SA's (NASDAQ: IPHA) data from the Phase 2 expansion cohort (cohort 3) evaluating the monalizumab triplet combination shows preliminary activity and an acceptable safety profile with a low discontinuation rate.
Innate Pharma to Present Monalizumab Data at ESMO Immuno-Oncology 2021 Congress
MARSEILLE, France, December 09, 2021--Monalizumab combined with cetuximab and durvalumab demonstrates anti-tumor activity in first-line r/m head and neck cancer at ESMO IO 2021 congress
Innate Pharma to Participate in the Evercore ISI 4th Annual HealthConX Virtual Conference
MARSEILLE, France, December 02, 2021--Innate Pharma to present monalizumab data at ESMO Immuno-Oncology 2021 Congress
Recently Viewed Tickers
MARSEILLE, France, November 24, 2021--Innate Pharma to participate in the Evercore ISI 4th Annual HealthConX Virtual Conference
Innate Pharma S.A. ADR
Visit a quote page and your recently viewed tickers will be displayed here.
About Innate Pharma
Innate Pharma SA is a biopharmaceutical company, which engages in improving oncology treatment and clinical outcomes for patients through therapeutic antibodies that harness the immune system to fight cancer. Its product pipeline include Lacutamab, Monalizumab, Avdoralimab, and IPH62.
Headlines
Innate Pharma S.A., a biotechnology company, discovers, develops, and commercializes therapeutic antibodies for the treatment of oncology indications in France and internationally.
Innate Pharma (NASDAQ:IPHA) Frequently Asked Questions
Innate Pharma: Monalizumab Combined With Cetuximab and Durvalumab Demonstrates Anti-Tumor Activity in First-Line Recurrent or Metastatic Head and Neck Cancer at ESMO Immuno ...
The Daily Biotech Pulse: Pfizer-BioNTech Partner For Shingles Vaccine, Annexon Huntington Disease Study Disappoints, Amneal Buys Neurology Assets
4 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for Innate Pharma in the last twelve months. There are currently 4 buy ratings for the stock. The consensus among Wall Street research analysts is that investors should "buy" Innate Pharma stock. View analyst ratings for Innate Pharma or view top-rated stocks.
18 Stocks Moving in Monday's Pre-Market Session
Here's a roundup of top developments in the biotech space over the last 24 hours.
About Innate Pharma
Gainers Creative Medical Technology Holdings, Inc. (NASDAQ: CELZ) rose 41.6% to $3.13 in pre-market trading after gaining around 8% on Friday.
Innate Pharma (OTCMKTS:IPHYF) Frequently Asked Questions
Innate Pharma SA is a biopharmaceutical company, which engages in improving oncology treatment and clinical outcomes for patients through therapeutic antibodies that harness the immune system to fight cancer. Its product pipeline include Lacutamab, Monalizumab, Avdoralimab, and IPH62.
